Subscribe

Dr. Agarwal's Eye Hospital Limited (DRAGARWQ.BO)

INR5,074.20 +39.25 (+0.78%)
IN BSE Healthcare Medical - Care Facilities
Address Buhari Towers
Chennai, IN
CEO Adil Agarwal
Website dragarwal.com
IPO 2024-12-30
ISIN INE934C01018

Explore sections of this company profile

Description

Dr. Agarwal's Eye Hospital Ltd. is a specialized medical facility offering a comprehensive range of ophthalmic services. Its extensive offerings span various specialties, encompassing cataract surgery, advanced corneal interventions (including LASIK and SMILE), retina treatment, orbit and oculoplasty, glaucoma management, uvea care, neuro-ophthalmology, pediatric ophthalmology, and strabismus correction, alongside optical dispensing. Beyond patient care, the hospital is committed to ongoing professional development through continuous training and actively participates in research and development initiatives. The company was established in 1957 by Jaiveer Agarwal, Tahira Agarwal, Amar Agarwal, and Athiya Agarwal, and maintains its primary operational base in Chennai, India.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR5,074.20 +39.25 (+0.78%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
444
Beta
-0.52
Float Shares
1.08M
Free Float %
22.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-3.24% -2.82% -1.31% +6.49% -3.43% -6.57% +14.53% +253.47% +1,130.60% +2,831.74% +71,099.29%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
5,074.20
DCF (Unlevered) 733.67 -85.5%
DCF (Levered) 2,447.31 -51.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2025-03 Change
Strong Buy 0 0
Buy 1 +1
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
4.64
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Care Facilities: +10.2%
    +18.6% ★ Q1'26: +20.1% (vs Q1'25)
  • ✓
    EPS growth Medical - Care Facilities: +19.2%
    +26.4% ★ Q1'26: -1.2% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Care Facilities: +32.0%
    +15.0% ★ Q1'26: +0.0% (vs Q1'25)
  • ✓
    EBIT margin Medical - Care Facilities: +11.3%
    +21.2% ★ Q1'26: +18.0% (vs Q1'25)
  • ✗
    ROIC Medical - Care Facilities: +6.8%
    +12.9% ★ Q1'26: +11.5% (vs Q1'25)
  • ✗
    Share dilution Medical - Care Facilities: +0.0%
    +1.5% Q1'26: +2.8% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×
    2.24× Q1'26: 2.42× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.43) × ERP
WACC = 88% × Ke + 12% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 733.67 Current price: 5,074.20
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana. 		Mar 2029
1 Rev. Ana.
1 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
1.18B
est: 1.17B (+1.0%)
1.37B
est: 1.23B (+11.2%)
1.49B
est: 1.50B (-1.1%)
1.53B
est: 1.62B (-5.5%)
1.75B
est: 1.82B (-3.6%)
1.40B
est: 2.00B (-30.2%)
3.97B
est: 1.23B (+223.4%)
1.23B
1.23B – 1.23B
+0.0% YoY
1.50B
1.50B – 1.50B
+22.3% YoY
1.62B
1.62B – 1.62B
+8.0% YoY
1.82B
1.82B – 1.82B
+12.1% YoY
2.00B
2.00B – 2.00B
+10.0% YoY
EBITDA
137.47M
est: 332.65M (-58.7%)
200.64M
est: 349.28M (-42.6%)
237.92M
est: 427.28M (-44.3%)
260.18M
est: 461.46M (-43.6%)
497.66M
est: 517.24M (-3.8%)
309.63M
est: 568.97M (-45.6%)
1.24B
est: 403.87M (+206.0%)
403.87M
403.87M – 403.87M
+0.0% YoY
494.05M
494.05M – 494.05M
+22.3% YoY
533.58M
533.58M – 533.58M
+8.0% YoY
598.08M
598.08M – 598.08M
+12.1% YoY
657.89M
657.89M – 657.89M
+10.0% YoY
EBIT
75.91M
est: 216.51M (-64.9%)
40.60M
est: 227.34M (-82.1%)
143.08M
est: 278.11M (-48.6%)
159.51M
est: 300.35M (-46.9%)
273.30M
est: 336.66M (-18.8%)
118.64M
est: 370.33M (-68.0%)
841.40M
est: 276.11M (+204.7%)
276.11M
276.11M – 276.11M
+0.0% YoY
337.77M
337.77M – 337.77M
+22.3% YoY
364.79M
364.79M – 364.79M
+8.0% YoY
408.89M
408.89M – 408.89M
+12.1% YoY
449.78M
449.78M – 449.78M
+10.0% YoY
Net Income
56.98M
est: 41.50M (+37.3%)
367.0K
est: 49.91M (-99.3%)
73.38M
est: 35.30M (+107.9%)
67.75M
est: 45.68M (+48.3%)
136.83M
est: 132.82M (+3.0%)
-14.39M
est: 158.29M (-109.1%)
546.50M
est: 50.64M (+979.3%)
50.64M
50.64M – 50.64M
+0.0% YoY
35.81M
35.81M – 35.81M
-29.3% YoY
46.34M
46.34M – 46.34M
+29.4% YoY
134.74M
134.74M – 134.74M
+190.7% YoY
160.59M
160.59M – 160.59M
+19.2% YoY
SGA
192.48M
est: 192.02M (+0.2%)
43.78M
est: 201.62M (-78.3%)
274.63M
est: 246.64M (+11.3%)
300.50M
est: 266.37M (+12.8%)
352.93M
est: 298.57M (+18.2%)
273.06M
est: 328.43M (-16.9%)
155.00M
est: 190.59M (-18.7%)
190.59M
190.59M – 190.59M
+0.0% YoY
233.15M
233.15M – 233.15M
+22.3% YoY
251.80M
251.80M – 251.80M
+8.0% YoY
282.24M
282.24M – 282.24M
+12.1% YoY
310.46M
310.46M – 310.46M
+10.0% YoY
EPS
12.12
est: 8.83 (+37.3%)
0.08
est: 10.62 (-99.2%)
15.61
est: 7.51 (+107.9%)
14.42
est: 9.72 (+48.4%)
29.11
est: 28.26 (+3.0%)
-3.06
est: 33.68 (-109.1%)
116.28
est: 10.62 (+994.9%)
10.62
10.62 – 10.62
+0.0% YoY
7.51
7.51 – 7.51
-29.3% YoY
9.72
9.72 – 9.72
+29.4% YoY
28.26
28.26 – 28.26
+190.7% YoY
33.68
33.68 – 33.68
+19.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-25 B 3/5 3/5 5/5 5/5 1/5 1/5 1/5
2026-05-22 B 3/5 4/5 5/5 5/5 1/5 1/5 1/5
2026-05-21 B 3/5 3/5 5/5 5/5 1/5 1/5 1/5
2026-05-20 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-08 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-07 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-06 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-05 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-04 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-30 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-29 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-28 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-27 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-24 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-23 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-22 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-21 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-20 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-17 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-04-16 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
684.39M
OE per share TTM
145.62
Owner's Yield
2.84%
Maintenance CapEx ratio
109.66%
Maint CapEx / Avg PPE
112.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
895.5K
Shares Outstanding
4.83M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Amar Agarwal MBBS Founder, Chairman & MD 39M —
Athiya Agarwal Founder & Whole Time Director 11M —
Meenakshi Jayaraman Company Secretary & Compliance Officer 2M female
Yashwanth Venkat Interim Chief Financial Officer 1M male
Adil Agarwal Chief Executive Officer & Whole -Time Director 300.0K —
N. R. Ugandhar Senior Vice President of International Operations of BD and M&A — male
Nandha Kumar Senior Vice President of Operations of South & East India — male
Suhasini Head of Human Resource — female
Terence Leo Seqi General Manager of Projects — —
Aman Joshi Head of Digital Marketing — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Care Facilities